Calyxt to Host First Quarter 2022 Financial Results Conference Call and Webcast on Thursday, May 5, 2022 at 4:30 p.m. EST

0

ROSEVILLE, Minn., April 21, 2022 /PRNewswire/ — Calixt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, will host a conference call and webcast at Thursday, May 5, 2022to 4:30 p.m. Eastern Time to discuss the results for the first quarter ended March 31, 2022. A press release detailing these results will be issued prior to the call.

Logo (PRNewsfoto/Calyxt, Inc.)

President and CEO, Michael A. Carrand Chief Financial Officer, Bill Koschak, will host the conference call, followed by a Q&A session. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the Investor Relations section of the Company’s website. here.

To access the call, please use the following information:

Date:
Weather:
Freephone number:
International/toll phone number:
Conference ID:

Thursday, May 5, 2022
4:30 p.m. EST, 1:30 p.m. PST
+1 888-317-6003
+1 412-317-6061
2452642

Participants should call the conference phone number 5-10 minutes prior to the start time. An operator will record the name and organization of each participant. The conference call will also be broadcast live and available for replay via the Investor Relations section of the Company’s website. here.

A replay of the webcast will be available for 30 days after the event.

Toll-free replay number:
International replay number:
Replay ID:

+1 877-344-7529
+1 412-317-0088
9265408

About Calixt:

Calyxt (Nasdaq: CLXT) is a plant-based synthetic biology company. The company leverages its proprietary PlantSpring™ technology platform to engineer plant metabolism to produce innovative, high-value plant-based chemicals for use in customer materials and products. As plant-based solutions, the company’s synthetic biology products can be used to help customers achieve their sustainability goals and financial goals. Calyxt’s diverse offerings are primarily supplied through its proprietary BioFactory™ production system. For more information, visit www.calyxt.com.

PlantSpring, BioFactory, Plant Cell Matrix™ and the Calyxt logo are registered trademarks of Calyxt, Inc. All other marks are the property of their respective owners.

Forward-looking statements

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. In some instances, you may identify these statements by forward-looking words such as “anticipates”, “believes,” “continue”, “estimate”, “expect”, “intend”, “may”, “could”, “plan”, “predict”, “project”, “should”, “target” , “will”, or the negative of these terms and other similar terms. Forward-looking statements in this press release include statements about the company’s future financial performance, including its cash trail; its product portfolio and development; its business model and strategies for developing, marketing and selling commercial products; commercial demand for its synthetic biology solutions; the development and deployment of its PlantSpring technology platform; its ability to deploy and leverage its artificial intelligence and machine learning (AIML) capabilities; the ability to increase the production capacity of its BioFactory production system; potential development agreements, partnerships, customer relationships and licensing agreements and their contribution to financial results, cash usage and growth strategies; the potential impact of the COVID-19 pandemic on its business and results of operations; and anticipated trends in its business. These and other forward-looking statements are predictions and projections of future events and trends based on the Company’s current expectations, objectives and intentions and are based on current assumptions. The actual results, level of activity, performance or achievements of the Company could differ materially from those expressed, implied or anticipated by the forward-looking statements due to a variety of factors, including, but not limited to : the impact of increased competition, including competition from a wider range of synthetic biology companies; competition for customers, partners and licensees and the successful execution of development and license agreements; disruptions at its key facilities, including disruptions affecting its BioFactory production system; defects in the AIML algorithms, insufficient data inputs required by such algorithms, and human error in interacting with AIML; changes in customer preferences and market acceptance of its products; changes in market consensus as to the attributes required for a product to be considered “sustainable”; the impact of adverse events during development, including failure of pilot plant-based chemical production or field trials; the impact of improper handling of its product candidates during development; failures of third party contractors; inaccurate demand forecasts or milestone and royalty payment projections; the effectiveness of commercial partners’ or licensees’ marketing efforts; disruptions to supply chains, including raw material inputs for its BioFactory; the impact of changes or increases in supervision and regulation; intellectual property disputes or disputes; the proliferation and continued evolution of new technologies; management changes; disruptions in capital markets; the severity and duration of the evolution of the COVID-19 pandemic and the resulting impact on macroeconomic conditions; and other important factors discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K. All forward-looking statements made by the Company’s management are based solely on information currently available and speak only as of the date of this report. Except as otherwise required by applicable securities and other laws, the Company undertakes no obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, if circumstances change, unless otherwise required by law.

contacts:

Calyxt Media Contact:

Calyxt Investor Relations Contact:

David Rosen / John Garabo / Michael Barron

Slang Partners

(212) 600-1902

[email protected]

Kimberly MinarovichCameron Willis

Slang Partners

(212) 600-1902

[email protected]

Quote

Quote

Show original content to download multimedia:https://www.prnewswire.com/news-releases/calyxt-to-host-first-quarter-2022-financial-results-conference-call-and-webcast-on-thursday-may-5-2022-at- 430-pm-eastern-time-301530052.html

SOURCECalyxt, Inc.


Source link

Share.

Comments are closed.